- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Mobia Medical, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | Mobia Medical, Inc.: Mobia Medical to Report Second Quarter 2026 Financial Results on August 11, 2026 | 1 | GlobeNewswire (USA) | ||
| 15.07. | Mobia Medical appoints Reza Zadno to board of directors | 1 | Investing.com | ||
| 15.07. | Mobia Medical beruft Medizintechnik-Veteranen Reza Zadno in den Verwaltungsrat | 3 | Investing.com Deutsch | ||
| 15.07. | Mobia Medical, Inc.: Mobia Medical Appoints Reza Zadno, Ph.D., to its Board of Directors | 132 | GlobeNewswire (Europe) | AUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor... ► Artikel lesen | |
| 15.07. | Mobia Medical, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.07. | Mobia Medical reports two-year stroke therapy data in Neurology | 1 | Investing.com | ||
| 14.07. | Mobia Medical, Inc.: Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim Paired VNS Therapy | 1 | GlobeNewswire (USA) | ||
| MOBIA MEDICAL Aktie jetzt für 0€ handeln | |||||
| 02.07. | Mobia Medical: CMS schlägt stabilen Vergütungssatz für Vivistim-Verfahren vor | 1 | Investing.com Deutsch | ||
| 02.07. | Mobia Medical, Inc.: Mobia Medical Announces Vivistim Procedure Remains Assigned to New Technology APC 1580 under CMS Proposed 2027 Hospital Outpatient Prospective Payment System Rule | 1 | GlobeNewswire (USA) | ||
| 04.06. | Mobia Medical, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 02.06. | Wolfe Research initiates Mobia Medical stock with outperform rating | 1 | Investing.com | ||
| 02.06. | BTIG initiates Mobia Medical stock coverage with buy rating | 1 | Investing.com | ||
| 02.06. | Goldman Sachs initiates Mobia Medical stock with buy rating on neuro tech | 2 | Investing.com | ||
| 02.06. | JPMorgan initiates Mobia Medical stock with Overweight rating | 1 | Investing.com | ||
| 02.06. | Mobia Medical: Goldman Sachs startet Coverage mit Kaufempfehlung dank Neurotechnologie | 5 | Investing.com Deutsch | ||
| 11.05. | Mobia Medical, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Mobia Medical, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 08.05. | Health stocks Odyssey, Mobia Medical disappoint on first day of trading | 1 | Seeking Alpha | ||
| 08.05. | MedTech firm Mobia Medical prices $150M IPO | 2 | Seeking Alpha |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEALWELL AI | 0,420 | +0,12 % | HEALWELL AI kündigt Telefonkonferenz zur Erörterung der Finanzergebnisse des zweiten Quartals 2026 für den 7. August 2026 an | HEALWELL AI wird am Freitag, den 7. August 2026, um 8:30 Uhr ET (5:30 Uhr PT) eine Telefonkonferenz und einen gleichzeitigen Webcast
abhalten
TORONTO, ON, 4. August 2026... ► Artikel lesen | |
| LIFEWARD | 7,200 | -6,13 % | Lifeward Out With Q2 Numbers | ||
| IMUNON | 1,380 | 0,00 % | Imunon Q2 2026 Earnings Preview | ||
| INSPIRE MEDICAL SYSTEMS | 51,50 | -1,90 % | Inspire Medical Systems, Inc. Announces Second Quarter 2026 Financial Results, Raised 2026 Guidance, and Strategic Growth Plan | Generated second quarter revenue of $200.6 millionSecond quarter diluted EPS of $0.01; adjusted diluted EPS of $0.14Second quarter operating cash flow of $23.2 millionAnnounced strategic growth plan... ► Artikel lesen | |
| INSPIREMD | 0,635 | -1,55 % | InspireMD Inc.: InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| GT BIOPHARMA | 0,320 | 0,00 % | GT Biopharma, Inc.: GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors | GTB-5550 is now the 3rd TriKE- to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation... ► Artikel lesen | |
| MYOMO | 1,248 | +1,30 % | Myomo expects $45M-$47M full-year revenue while targeting second-half cash burn below $2M | ||
| INOGEN | 5,950 | +13,33 % | Inogen Inc - 10-Q, Quarterly Report | ||
| INTELLIGENT BIO SOLUTIONS | 1,990 | +0,51 % | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission | NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| INCANNEX HEALTHCARE | 3,155 | 0,00 % | Incannex Healthcare: Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea | First clinical sites approved and actively screening potential participantsRepresents another major milestone in the advancement of IHL-42X towards Phase III developmentIHL-42X has received FDA Fast... ► Artikel lesen | |
| GLUCOTRACK | 0,432 | 0,00 % | Glucotrack Secures $5.5 Million Financing Through Equity And Convertible Debt | ||
| LEXARIA BIOSCIENCE | 5,450 | +3,42 % | Lexaria Bioscience Corp.: Lexaria Announces Effective Date for Reverse Stock Split | KELOWNA, BC / ACCESS Newswire / July 30, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it intends to effect... ► Artikel lesen | |
| LENSAR | 6,070 | +0,50 % | LENSAR, Inc.: LENSAR to Report Second Quarter 2026 Results on August 13th, 2026 | ||
| HEARTBEAM | 0,524 | 0,00 % | HeartBeam receives patent for multi-modal cardiac sensing device | ||
| MINIMED GROUP | 15,698 | -7,59 % | MiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors | David Endicott, Chief Executive Officer of Alcon, brings global healthcare leadership and public company experience; Linnea Burman adds MedTech operating depth NORTHRIDGE, Calif., June... ► Artikel lesen |
Das Unternehmen MOBIA MEDICAL INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 12,070 Euro und damit -1,39 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOBIA MEDICAL INC finden Sie auf Wallstreet Online.